GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

Year in Review 2024 - Hepatobiliary Cancers

Oncology 2024 Year in Review

R. Kim, T. Biachi

ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunot…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

Multidisciplinary Approach to Hepatocellular Carcinoma

UCLA Health

G. Choi, B. Yanny, S. Sadeghi, J. Hui

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

ESMO 2024 Summary: Highlights in HCC

2024 ESMO Annual Meeting Insights Hub

R. Kim, T. Biachi

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - P…

2024 ESMO Annual Meeting Insights Hub

J. Llovet

ESMO 2024 Summary: Updates in HCC and Impacts on Practice

2024 ESMO Annual Meeting Insights Hub

H. Babiker

Updates in Hepatocellular Carcinoma

Michigan Medicine

N. Razumilava

ESMO 2024 Insights: CheckMate 9DW Expanded Analysis - Nivo + Ipi vs.…

2024 ESMO Annual Meeting Insights Hub

H. Karachiwala

Expert Panel on TACE and TARE for HCC: Weighing the Pros and Cons

Integrity CE

M. Pishvaian, R. Salem

ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvaluma…

2024 ESMO Annual Meeting Insights Hub

L. Rimassa

Cancer Screening Molecular Tools

Fengting Yan

Choosing the Best HCC Treatment Based on Patient and Disease Stage

Integrity CE

M. Pishvaian, R. Finn, R. Salem, A. Singal

Hepatic Arterial Infusion Therapy for CRC Liver Mets and Unresectabl…

Yale Cancer Center

J. Kortmansky, S. Khan

Impact of Neoadjuvant IO on Recurrence-Free Survival in High-Risk Lo…

Johns Hopkins

M. Nakazawa

ASCO® 2024 Summary: "Experts Discuss Key Studies in HCC and BTC"

2024 ASCO® Annual Meeting Insights Hub

R. Kim, T. Biachi